First-line liposomal irinotecan+5 fluorouracil/leucovorin plus oxaliplatin in patients with pancreatic ductal adenocarcinoma: Long-term follow-up results from a phase 1/2 study

被引：2
|
作者：
Wainberg, Z. [1 ]
Bekaii-Saab, T. [2 ]
Boland, P. [3 ]
Dayyani, F. [4 ]
Macarulla, T. [5 ,6 ]
Mody, K. [5 ,6 ,7 ]
Belanger, B. [8 ]
Maxwell, F. [9 ]
Moore, Y. [8 ]
Thiagalingam, A. [8 ]
Wang, T. [8 ]
Zhang, B. [8 ]
Dean, A. [10 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Mayo Clin Phoenix, Phoenix, AZ USA
[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[4] Univ Calif Irvine, Med Ctr, Orange, CA 92668 USA
[5] Vall dHebron Univ Hosp, Barcelona, Spain
[6] Vall dHebron Inst Oncol, Barcelona, Spain
[7] Mayo Clin, Jacksonville, FL 32224 USA
[8] Ipsen, Cambridge, MA USA
[9] Ipsen, Abingdon, Oxon, England
[10] St John God Subiaco Hosp, Dept Oncol, Subiaco, WA, Australia
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA-1
引用
收藏
页码：S241 / S241
页数：1
相关论文
共 50 条
  • [1] First-line liposomal irinotecan+5 fluorouracil/leucovorin plus oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
    Dean, A.
    Bekaii-Saab, T.
    Boland, P. M.
    Dayyani, F.
    Macarulla Mercade, T.
    Mody, K.
    Belanger, B.
    Maxwell, F.
    Moore, Y.
    Thiagalingam, A.
    Wang, T.
    Zhang, B.
    Wainberg, Z. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1313 - S1314
  • [2] First-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin in patients with pancreatic ductal adenocarcinoma: results from a phase 1/2 study
    Dean, Andrew
    Bekaii-Saab, Tanios
    Boland, Patrick M.
    Dayyani, Farshid
    Macarulla, Teresa
    Mody, Kabir
    Belanger, Bruce
    Maxwell, Fiona
    Moore, Yan
    Thiagalingam, Arunthathi
    Wang, Tiffany
    Zhang, Bin
    Wainberg, Zev A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 118 - 119
  • [3] First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study
    Wainberg, Zev A.
    Bekaii-Saab, Tanios
    Boland, Patrick M.
    Dayyani, Farshid
    Macarulla, Teresa
    Mody, Kabir
    Belanger, Bruce
    Maxwell, Fiona
    Moore, Yan
    Thiagalingam, Arunthathi
    Wang, Tiffany
    Zhang, Bin
    Dean, Andrew
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 14 - 24
  • [4] First-line liposomal irinotecan+5 fluorouracil/leucovorin plus oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
    Dean, A.
    Bekaii-Saab, T.
    Boland, P. M.
    Dayyani, F.
    Macarulla Mercade, T.
    Mody, K.
    Belanger, B.
    Maxwell, F.
    Moore, Y.
    Wang, T.
    Zhang, B.
    Wainberg, Z. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1314 - S1315
  • [5] nITRO: A phase 2 study of perioperative liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) in patients with resectable pancreatic ductal adenocarcinoma (rPDAC).
    Melisi, Davide
    Zecchetto, Camilla
    Merz, Valeria
    Malleo, Giuseppe
    Landoni, Luca
    Quinzii, Alberto
    Casalino, Simona
    Gaule, Marina
    Pesoni, Camilla
    Casetti, Luca
    Esposito, Alessandro
    Piazzola, Cristiana
    D'Onofrio, Mirko
    de Robertis, Riccardo
    Gabbrielli, Armando
    Luchini, Claudio
    Butturini, Giovanni
    Scarpa, Aldo
    Salvia, Roberto
    Bassi, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 701 - 701
  • [6] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
    Dean, Andrew
    Wainberg, Zev A.
    Bekaii-Saab, Tanios S.
    Hubner, Richard
    Macarulla, Teresa
    Paulson, Andrew Scott
    Cutsem, Eric V.
    Maxwell, Fiona
    Moore, Yan
    Wang, Haofei Tiffany
    Zhang, Bin
    O'Reilly, Eileen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 202 - 203
  • [7] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
    Wainberg, Zev A.
    Bekaii-Saab, Tanios S.
    Hubner, Richard
    Macarulla, Teresa
    Paulson, Andrew Scott
    Van Cutsem, Eric
    Maxwell, Fiona
    Moore, Yan
    Wang, Haofei Tiffany
    Zhang, Bin
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma A Single-Center Real-World Study
    Chiang, Cho-Han
    Chiang, Cho-Hung
    Chiang, Cho-Hsien
    Chiu, Jing-Huey
    Ma, Kevin Sheng-Kai
    Chen, Brian Shiian
    Luan, Yu-Ze
    Cheng, Teng-Chieh
    Hsieh, Ching-Lung
    Peng, Cheng-Ming
    PANCREAS, 2022, 51 (08) : E107 - E109
  • [9] FOLFOX (oxaliplatin and leucovorin plus fluorouracil) versus FOLFIRI (irinotecan and leucovorin plus fluorouracil) chemotherapy as a first-line treatment in a patients with unresectable metastatic or recurred gastric adenocarcinoma
    Tak, Dae Hyun
    Kim, Seok Hyun
    Moon, Hee Seok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 261 - 261
  • [10] First-line (1L) liposomal irinotecan+5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): Exploratory subgroup analyses of survival by changes in CA 19-9 levels
    Dean, A.
    Bekaii-Saab, T.
    Boland, P. M.
    Dayyani, F.
    Macarulla, T.
    Mody, K.
    Belanger, B.
    Maxwell, F.
    Moore, Y.
    Wang, T.
    Zhang, B.
    Wainberg, Z. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S941 - S942
12345